Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial comparing SIAC once daily versus insulin glargine once daily in type 2 diabetes mellitus
2008-005767-34Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c at 26 weeks. Started Aug 2009; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-005767-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005767-34.